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Pyrrolobenzodiazepines (PBDs) Do Not Bind to DNA
G-Quadruplexes
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Abstract
The pyrrolo[2,1-c][1,4] benzodiazepines (PBDs) are a family of sequence-selective, minor-groove binding DNA-interactive
agents that covalently attach to guanine residues. A recent publication in this journal (Raju et al, PloS One, 2012, 7, 4,
e35920) reported that two PBD molecules were observed to bind with high affinity to the telomeric quadruplex of
Tetrahymena glaucoma based on Electrospray Ionisation Mass Spectrometry (ESI-MS), Circular Dichroism, UV-Visible and
Fluorescence spectroscopy data. This was a surprising result given the close 3-dimensional shape match between the
structure of all PBD molecules and the minor groove of duplex DNA, and the completely different 3-dimensional structure of
quadruplex DNA. Therefore, we evaluated the interaction of eight PBD molecules of diverse structure with a range of
parallel, antiparallel and mixed DNA quadruplexes using DNA Thermal Denaturation, Circular Dichroism and Molecular
Dynamics Simulations. Those PBD molecules without large C8-substitutents had an insignificant affinity for the eight
quadruplex types, although those with large p-system-containing C8-substituents (as with the compounds evaluated by
Raju and co-workers) were found to interact to some extent. Our molecular dynamics simulations support the likelihood
that molecules of this type, including those examined by Raju and co-workers, interact with quadruplex DNA through their
C8-substituents rather than the PBD moiety itself. It is important for the literature to be clear on this matter, as the
mechanism of action of these agents will be under close scrutiny in the near future due to the growing number of PBD-
based agents entering the clinic as both single-agents and as components of antibody-drug conjugates (ADCs).
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Introduction
The pyrrolo[2,1-c][1,4] benzodiazepines (PBDs) are a group of
sequence-selective DNA minor-groove binding agents originally
discovered in Streptomyces species [1,2,3,4,5]. Anthramycin (1,
Figure 1) was the first PBD to be isolated and studied [6],
although more than twelve naturally occurring PBDs are now
known [1]. They are characterized by an electrophilic N10–C11
imine group (or the hydrated equivalent) which forms a reversible
covalent aminal linkage from their C11-position to the C2-NH2
group of a guanine in the DNA minor groove [7,8]. Crucially, the
molecules have (S)-chirality at their C11a-position, and this
provides them with the appropriate 3-dimensional shape (i.e.,
isohelicity) to fit perfectly into the DNA minor groove. PBD/DNA
adduct formation has been shown to inhibit a number of biological
processes, including the binding of transcription factors to DNA
[9,10,11,12] and the function of enzymes such as endonucleases
[13,14] and RNA polymerase [15]. Many PBD molecules also
have significant antimicrobial activity [16,17,18,19,20,21].
PBD monomers have been shown by footprinting [7], NMR
[22,23], molecular modeling [24] and X-ray crystallography [25]
to span three base pairs with a reported preference for orientation
of their A-ring toward the 39-end of the covalently-modified strand
(i.e., A-Ring-39) [26], although a recent report suggests that the A-
ring can orientate toward either the 39- or 59-ends [27]. In the
past, PBD molecules have been reported to prefer 59-Pu-G-Pu-
39sequences [26,28], although more recent data suggest that they
have a kinetic preference for 59-Py-G-Py-39 motifs [27] (where Pu
= purine, Py = pyrimidine, G = reacting guanine). PBDs are
thought to interact with DNA by first locating a low-energy
binding site through van der Waals (vdW), H-bonding and
electrostatic interactions [29]. Once in place, nucleophilic attack
by the exocyclic C2-NH2 of the central guanine then occurs to
form a covalent adduct [29]. Once bound, the PBD remains
anchored in the DNA host minor groove, avoiding DNA repair
through negligible distortion of the helix [25]. It is well-established
that PBDs are highly selective in requiring minor groove structure
in either duplex or hairpin DNA for covalent binding to occur,
and they do not bind to single stranded DNA (or RNA) regardless
of its GC content and/or length [30].
Synthetic PBD monomers with non-covalent DNA-interactive
components joined to the C8-position of their A-rings have also
been reported [29,31,32,33,34], and examples such as GWL-78
(4, Figure 1) [29] and KMR-28-18 (5, Figure 1) [12] can span
up to six or seven base pairs. Furthermore, two PBD units have
been joined through their C7- [35] or C8-positions (i.e., 6-8,
Figure 1) to form PBD dimers with the ability to form inter- and
intra-strand DNA cross-links [36,37]. One example (SJG-136, 6)
[38] is presently in Phase II clinical trials as an anti-cancer agent
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[39,40,41]. Both PBD monomers and dimers have a common
feature in that their covalent interaction in the minor groove
significantly enhances the stability of the DNA double helix to
thermal denaturation [26,29,42], and this stabilizing property
correlates well with their in vitro cytotoxicity [29,38,42].
Although B-Form DNA is the predominant type present in cells,
it is now known that single-stranded guanine-rich nucleic acid
sequences can fold into four-stranded structures comprised of
stacked tetrads formed by Hoogsteen hydrogen bonding of four
guanines, stabilized overall by monovalent cations such as K+.
These structures, known as G-quadruplexes (or G4s), are classified
by their sequence, stoichiometry, polarity of each strand, how the
loops connect the different strands, and the conformation of
guanine glycosidic angles. For example, G-quadruplexes can be
classified as uni-, bi- or tetra-molecular, and can have differences
in loop directionality (e.g., parallel or antiparallel) and length.
Certain proteins known as telomere end-binding proteins (TEBPs)
can promote G-quadruplex formation under the control of the cell
cycle machinery [43].
G-quadruplexes may form in telomeric DNA repeats as well as
in sequences in the promoter and other regulatory regions within
human and other genomes. The human genome has been
surveyed for putative G4-forming sequences, and over 250,000
non-overlapping sequences have been identified [43], with many
over-represented in promoter regions and in the first intron [44] of
a variety of genes. Putative G4-forming regions of DNA have at
least four runs of three or more consecutive guanines (G-tracts)
separated by varying nucleotides that comprise the loop structures.
Negative superhelicity induced by transcription can promote local
unwinding of these G/C-rich duplex regions of DNA, allowing for
the formation of G4s. Interestingly, a correlation has been found
between the frequency of occurrence of these sequences in
promoter regions and the nuclease hypersensitivity of these sites.
Even though G4 formation has to compete with the stable duplex
DNA form, a number of studies have shown that G4 structures
can be induced under conditions which mimic the intracellular
environment, and that they can have significant biological
consequences [45,46]. Crucially, G4s have recently been shown
to form in cells, and to play a role in modulating transcription
[47,48,49]. Their unique, non-B-form globular structure, and their
potential to regulate the transcription of a range of oncogenes,
have made G4s an attractive target for the development of novel
anticancer agents. For example, a number of genes involved in the
proliferation of tumour cells such as C-myc, c-Kit, BCL2 and K-ras
are known to contain G4-forming sequences in their promoter
regions [50] and are being targeted. In a number of these, stable
G4 structures have been demonstrated to form using biophysical
methods, and in others (e.g., C-myc, c-Kit, K-ras, PDGFA and
BCL2) [51,52] the molecular structures of promoter quadruplexes
have been characterized by high-field NMR.
Despite the fact that it is well-established that G-quadruplexes
do not possess any B-form duplex DNA structure or minor groove
environment, and that it is known that small molecules can
discriminate between DNA duplex and quadruplex architectures
[50], Raju and co-workers recently reported [53] that two DNA
minor-groove binding PBD molecules, the C8-linked PBD-pyrene
conjugate (9, Figure 2) and the mixed N10-C11/N10’-C11’
imine-lactam pyrrolobenzodiazepine dimer (10, Figure 2) bind
with high affinity to the G-quadruplex formed in a telomeric
region of DNA from Tetrahymena Glaucoma. This was surprising
given the extensive literature on PBD agents since the 1960s, all of
which highlight the close 3-dimensional fit of these molecules in
Figure 1. Structures of the PBD monomers and dimers used in the current study. Anthramycin methyl ether (1), the PBD-C8-ester (2) and
the PBD-C8-morpholine (3) do not possess any p-systems in their C8-side chains, whereas the PBD C8-conjugates 4 and 5 both have C8-substituents
consisting of aromatic rings. The three PBD dimers, SJG-136 (6), DRG-16 (7) and ELB-21 (8) have structural similarity to the PBD dimer (PBD2, 10)
evaluated by Raju and co-workers [53] (see Figure 2).
doi:10.1371/journal.pone.0105021.g001
Pyrrolobenzodiazepines (PBDs) and G-Quadruplexes
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the minor groove of B-Form DNA [26,28]. It is also known that
PBDs do not bind to RNA due to the lack of a minor groove
environment in this type of nucleic acid structure [54]. In addition,
we have previously used PBD molecules as negative controls in
screens searching for quadruplex-binding ligands (un-reported
results).
This prompted us to carry out a detailed evaluation of the
potential interaction of eight pyrrolobenzodiazepine molecules of
both monomer (1–5) and dimer (6–8) types of diverse structure
(Figure 1) with eight different G-quadruplex-forming sequences
including the same Tetrahymena glaucoma sequence used by Raju
and co-workers [53] (Table 1). To evaluate quadruplex versus
duplex binding, we initially utilised a well-established FRET-based
melting assay [55,56], along with a control biaryl polyamide
molecule KMR-04-12 (11, Figure 3), previously reported [55] to
be highly selective for quadruplex versus duplex DNA. Despite
evaluating the eight pyrrolobenzodiazepine compounds up to very
high concentrations (i.e., 5:1 to 50:1 ligand/DNA molar ratios), six
did not show any significant stabilisation of any of the eight G-
quadruplex structures, whereas GWL-78 (4) and KMR-28-18 (5)
had modest stabilizing properties (i.e., up to DTm = 2.9 uC) at the
highest concentration tested (i.e., 50 mM, 50:1 ligand/DNA molar
ratio). This compared to a DTm value of up to 25.1uC for the
positive quadruplex-binding control molecule 11 at the same
concentration and molar ratio. Conversely, when the PBDs were
evaluated against duplex DNA at the same concentration and
molar ratio, DTm values ranged from 4.5uC for the simple PBD
C8-Ester (2) to 28uC for the PBD dimer SJG-136 (6), whereas the
quadruplex-binding control molecule 11 had a DTm of only 1.1uC
at the same concentration and molar ratio.
It is noteworthy that 4 and 5 have the longest C8-substituents of
all the PBDs evaluated. Significantly, the isolated PBD core unit
alone with the short C8-substituent (2, Figure 1) had no
stabilising properties toward quadruplex DNA, confirming that it
was the MPB-Py-Py C8-substituent itself rather than the PBD
component providing the quadruplex binding properties. To
investigate this further, the isolated MPB-Py-Py fragment (12,
Figure 3) that comprises the C8-substituent of 5 was evaluated
and found to have a DTm value of up to 2.9uC at a 50:1 ligand/
DNA molar ratio. In the case of the PBD1 (9) and PBD2 (10)
molecules studied by Raju and co-workers [53], it is likely that a
similar phenomenon was taking place during their experiments,
with the relatively bulky C8-substituents binding to the quadruplex
DNA rather than the PBD components. In our study, the relative
lack of interaction of the eight PBD molecules with the different
quadruplex sequences was further confirmed by CD spectroscopy
which failed to show any notable change in the characteristic
signals after the addition of up to 10 molar equivalents of ligands.
Molecular modeling studies also supported these observations.
Materials and Methods
Fluorescence Resonance Energy Transfer (FRET) Assay
Oligonucleotide sequences used for the FRET-based DNA
thermal denaturation assays (see Table 1) were purchased from
Eurogentec, Southampton, UK. TAMRA (6-carboxytetramethylr-
hodamine) and FAM (6-carboxyfluorescein) are acceptor and
donor fluorophores, respectively. From 20 mM stock solutions,
400 nM solutions in FRET buffer (optimized as 50 mM potassi-
um, 50 mM cacodylate, pH 7.4) were prepared prior to use. The
oligonucleotides were annealed through heating the samples to
90uC for 10 mins followed by cooling to room temperature and
storing at this temperature for 5 h. Dilutions from the initial 5 mM
DMSO stock solution were performed using FRET buffer.
Figure 2. Structures of the C8-substituted PBD-Pyrene conjugate (PBD1, 9) and the PBD dimer (PBD2, 10) reported by Raju and co-
workers to bind to quadruplex DNA [53].
doi:10.1371/journal.pone.0105021.g002
Figure 3. Structures of the G-quadruplex-interacting ligand KMR-04-12 (11), and the MPB-Py-Py fragment (12) identical to the C8-
side chain of KMR-28-18 (5). The MPB moiety in the centre of KMR-04-12 (11) provides the molecule with a U-shaped 3-dimensional shape
suitable for binding to G-quadruplex DNA.
doi:10.1371/journal.pone.0105021.g003
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Annealed DNA (25 mL) and sample solution (25 mL) were added
to each well of a 96-well plate (MJ Research, Waltham, MA), and
processed in a DNA Engine Opticon (MJ Research). Fluorescence
readings were taken at intervals of 0.5uC over the range 30–
100uC, with a constant temperature maintained for 30 seconds
prior to each reading. Incident radiation of 450–495 nm was used,
with detection at 515–545 nm. The raw data were imported into
the program Origin (Version 7.0, OringinLab Corp.), and the
graphs were smoothed using a 10-point running average, and then
normalized. Determination of melting temperatures was based on
values at the maxima of the first derivative of the smoothed
melting curves using a script. The difference between the melting
temperature of each sample and that of the blank (DTm) was used
for comparative purposes.
Circular Dichroism and Thermal Denaturation Studies
The UV & CD spectra of the oligonucleotides and oligonucle-
otide/ligand complexes were acquired using a Chirascan-Plus
Spectrometer (Applied Photophysics Ltd, Leatherhead, UK). The
UV absorbance and CD spectra were measured between 500–
200 nm in a strain-free rectangular 5 or 10 mm cell. The
instrument was flushed continuously with pure evaporated
nitrogen throughout the measurements. Spectra were recorded
using a 1 nm step size, a 1 s time-per-point and a spectral
bandwidth of 1 or 2 nm. Addition of the ligands to the
oligonucleotide solutions was carried out while maintaining a
constant concentration of DNA. All spectra were acquired at room
temperature and the buffer baseline corrected. All CD spectra
were smoothed using the Savitsky-Golay method, and a window
factor of 4–12 was used for better presentation.
The Dynamic Multi-mode Spectroscopy (DMS) technology
provided by Applied Photophysics Ltd was employed for the
thermal measurements. The CD spectra were first recorded at
room temperature (20uC), then after cooling to 6uC, heating to the
highest temperature (94uC), re-cooling to 6uC and finally heating
back to 20uC. The melting profiles monitored at a particular
wavelength were recorded during both the heating and cooling
processes. The instrument was equipped with a Quantum
(NorthWest, USA) TC125 Peltier unit set to change temperature
from 6R94uC at a rate of 1uC/min with a 2uC step-size. The
same parameters were set for the cooling process (94R6uC). A 2 s
time-per-points CD measurement time scale was employed in the
400–215 nm region with a 2 nm spectral bandwidth. Tempera-
ture was measured directly using a thermocouple probe in the
solutions. Melting temperatures were determined from derivative
spectra produced using the Global Analysis T-Ramp software
(Applied Photophysics Ltd).
Molecular Modeling Studies
All MD simulations were performed using the AMBER 11
software package [57].
Ligand Preparation. The PBD structures KMR-28-18 (5),
DRG-16 (7), PBD1 (9) and PBD2 (10) were constructed using the
Schro¨dinger Maestro software, and the dihedrals of each structure
were rotated to maintain the known curved nature (‘‘isohelicity’’)
of the PBD molecules. AMBER antechamber was used to assign
partial atomic charges to each ligand using the Gasteiger charging
system, and missing parameters were generated for each ligand
using AMBER parmchk. Ligands were then energy minimized
using the MMFF94 energy gradient.
Receptor Preparation. Structural co-ordinates of the G-
quadruplex receptor file were obtained from the Protein Data
Bank (PDB ID: 3CDM) [58]. The coordinates were subjected to
molecular mechanics minimization (1000 steps steepest descent,
followed by 3000 steps of Polak-Ribiere conjugate gradient
minimization with a derivative convergence of 0.05 kJ A˚ 21
mol), followed by molecular dynamics simulation (40 ps at 300 K
equilibrium using a 1.5 fs time-step). A final molecular mechanics
minimization (Polak-Ribiere conjugate gradient) of the average co-
ordinates of the previous MD step was then undertaken to obtain a
final model of low energy for use in ligand:DNA studies [59].
DNA-Drug Adduct Simulation. AMBER xleap was used to
align each ligand with the outer face of the quadruplex structure,
with initial coordinate and topology files established using ff99bsc0
force field parameters [60] (for DNA) and gaff parameters for
each ligand. AMBER xleap was used to automatically place 21 K+
counter-ions around the quadruplex structure, and a 12 A˚
truncated octahedral periodic water solvent box (TIP3P) and
periodic boundary conditions were created for use in simulations.
Initial energy minimization was undertaken with DNA restrained
at a high force constant (500 kcal mol21 A˚22), which was reduced
in stages to zero. In the first stage of MD simulation, a 30 ps
simulation was performed where the system was heated slowly
from 0 K to 300 K using the Langevin thermostat (and a collision
frequency of 1.0 ps21). Following this, an equilibration step was
undertaken over 100 ps with constant pressure and no restraints.
Production dynamics simulations were then run over a time-scale
of 10 ns (constant volume, 300 K temperature) with a 2 fs time
step. The SHAKE algorithm was applied to restrain hydrogen
atoms, thereby removing the highest frequency oscillation and
Table 1. G-Quadruplex-forming oligonucleotides used in this study.
Source Gene Topology in K+ Buffera Base Pair Sequence
F21T M 59-FAM-GGGTTAGGGTTAGGGTTAGGG-TAMRA-39
FT2G8 P 59-FAM-GGGGTTGGGG-TAMRA-39
c-Kit1 A 59-FAM-d(G3AG3CGCTG3AG2AG3)-TAMRA-39
c-Kit2 A 59-FAM-d(G3CG3CGCGAG3AG4)-TAMRA-39
C-myc P 59-FAM-TGGGGAGGGTGGGGAGGGTGGGGAAGG-TAMRA-39
K-ras P 59-FAM-GGGAGGGAGGGAAGGAGGGAGGGAGGGA-TAMRA-39
STAT3 P 59-FAM-GGGCTGGGGATGGGGAGGGGG-TAMRA-39
BCL2 P 59-FAM-GGGCGCGGGAGGGAAGGGGGCGGG-TAMRA-39
Duplex 59-FAM-(TA)2GC(TA)2AGAT6TCT(TA)2GC(TA)2-TAMRA-39
aM = Mixed Parallel/Anti-Parallel; P = Parallel; A = Anti-Parallel.
doi:10.1371/journal.pone.0105021.t001
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permitting the use of a 2 fs time-step, with all simulations
undertaken using AMBER pmemd. Molecular dynamics simula-
tions were visualised using VMD [61], and models were created
using Chimera [62].
Free Energy of Binding Calculations. Binding free energy
was calculated using the following equation:
DG0bind~DG
0
bind vacuumzDG
0
complex-(DG
0
ligandzDG
0
receptor),
where DGubind was determined by solving the linearized Poisson-
Boltzmann equation [63]:
DG0complex~EMMzGpolar solvation energyzGnonpolar solvation energy-TS
Solvation energies (both polar and non-polar) were considered,
with EMM corresponding to internal, electrostatic and van der
Waal interactions, and S to solute entropy.
The final binding energy was represented using the equation:
DG0bind~DEMMzDG
0
solv-TDS
Entropic calculations were not undertaken as they are
computationally expensive and are prone to introducing signifi-
cant errors into the calculation of free energy of binding values.
Furthermore, due to the fact that similar entropic states (i.e.,
identical receptors and structurally similar ligands) were analyzed,
computationally expensive entropic calculations would have added
little value to the free energy of binding results. One hundred
snapshots of the MD simulations were taken at equal intervals over
the 10 ns duration, and molecular mechanics (MM) calculations
were performed using pbsa [64].
Results and Discussion
The initial experiments involved measurement of the interaction
of PBDs 1–8 (Figure 1) and the quadruplex-binding control
molecule 11 (Figure 3) with the eight quadruplex-forming DNA
sequences and the control DNA duplex shown in Table 1 using
the Fluorescence Resonance Energy Transfer (FRET) thermal
denaturation assay described in the Materials and Methods
section. FRET assays are widely used to determine melting
temperatures of different DNA sequences and ligand-DNA
complexes [65,66], and the FRET phenomenon has been
extensively used to study the stability of nucleic acid structures
and, in particular, G-quadruplex DNA [65]. In the FRET-based
G-quadruplex melting assay used in this study, 6-carboxyfluor-
escein (FAM) and 6-carboxytetramethylrhodamine (TAMRA)
were used as donor and acceptor FRET moieties attached to the
59- and 39- ends of the DNA, respectively, via 6-carbon linkers
[66]. The FAM/TAMRA fluorophore pair has a Forster radius
(Ro) of approximately 5 nm, and when the labeled sequences form
G-quadruplexes, the two are located close enough to allow FRET
to occur efficiently. Application of external energy in the form of
heat unfolds the quadruplex causing the fluorophores to separate
from each other, thus reducing the FRET efficiency and
generating a signal through a consequent increase in the intensity
of radiation emitted by the donor.
The results (Table 2) confirm that the PBD monomers without
heterocycle-containing C8-substituents (1–3), all failed to stabilise
the eight G-quadruplex sequences even at a molar ratio of 50:1
(Ligand:G-quadruplex - 10 uM:0.2 uM and 50 mM:1 mM). This
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was anticipated, as the molecules are not planar and contain no
appreciable p-ring systems (apart from the PBD A-ring) that can
interact with the quadruplex structure, a known means to enhance
ligand/quadruplex affinity [67,68]. On the other hand, the PBD-
C8 conjugates with p-ring-containing C8-substituents (4 and 5)
showed negligible stabilisation at a molar ratio of ligand/
quadruplex of up to 5:1, but a modest increase in melting
temperatures (i.e., up to 2.4uC) of almost all the G-quadruplexes at
a 25:1 ratio (Ligand:G-quadruplex - 5 uM:0.2 uM), increasing
marginally to up to 2.9uC at a 50:1 molar ratio (Ligand:G-
quadruplex - 10 uM:0.2 uM and 50 mM:1 mM). This suggested
that, for these molecules, the stabilisation was due to the
heterocyclic rings attached to the C8-positon, particularly as the
shorter C8-substituent of 4 led to a lower enhancement in Tm than
the longer side chain of 5. To probe this further, we evaluated the
dipyrrole-MPB moiety 12 (Figure 3), identical in structure to the
C8-substituent of KMR-28-18 (5), at the same concentrations as
used for the PBD-C8 conjugates. Interestingly, it produced an
almost identical interaction profile, stabilising all of the different
G-quadruplex sequences by up to 2.1uC at a 50:1 molar ratio
(Ligand:G-quadruplex - 10 uM:0.2 uM and 50 mM:1 mM). This
result, coupled with the fact that the simple PBD monomers 1–3
had no quadruplex stabilising activity of their own even at the
highest concentration and molar ratio, confirmed that PBD
structures themselves are not capable of stabilizing DNA
quadruplex.
Next, we studied the PBD dimers 6–8 for their ability to interact
with and stabilise the G-quadruplex sequences. PBD dimers 7 and
8 are similar to the PBD2 (10) molecule (Figure 2) studied by
Raju and co-workers in having a C8/C8’-dioxypentenyl linker
joining the two A-rings of the PBD units. Although they contain
N10-C11/N10’-C11’ imine moieties rather than the mixed imine/
dilactam functionalities present in PBD2 (10) at these positions,
this does not affect their length or 3-dimensional shape (see
Figure 4). However, no stabilisation was observed for any of the
quadruplex-forming sequences at molar ratios of up to 10:1
(ligand:G-quadruplex). The shorter PBD dimer SJG-136 (6) that
contains a C8/C8’-dioxypropenyl linker was similarly non-
Figure 4. A, Comparison of length and 3-dimensional shape between the PBD dimer (PBD2, 10) used in the G-quadruplex studies reported by Raju
and co-workers [53] and the PBD dimers 7 and 8 used in this study; B, Overlay of the three PBD dimers (7, 8 and 10) confirming their
superimposability.
doi:10.1371/journal.pone.0105021.g004
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interactive. A modest increase in melting temperature was
observed for all three PBD dimers (i.e., up to 1.7uC) at the higher
50:1 ratio (Ligand:G-quadruplex - 10 uM:0.2 uM), most likely due
to a non-selective interaction with the loop sequences where the
dimers may be able to form hairpin-like structures around the
DNA bases at such high concentrations.
To further confirm the lack of interaction of PBD monomers
and dimers with G-quadruplex sequences, CD titration and CD
melting studies were carried out with the PBD monomer
anthramycin (1) and the C8-linked PBD-morpholine conjugate 3
with the human telomeric G-quadruplex sequence HT4. This
quadruplex was selected as it is one of the most studied structures,
and a number of CD titration experiments with G-quadruplex-
binding ligands have been reported [45,51,56,67,69]. The CD
spectrum of the HT4 sequence showed the characteristic presence
of mixed parallel and antiparallel structures with positive peaks
around 295 nm and a negative peak around 240 nm (Figure 5).
Neither 1 or 3 produced any notable changes in the CD signals at
the highest ratio evaluated (5:1; ligand:HT4). Furthermore, no
change in melting temperatures in the presence or absence of the
ligands was observed in the CD melting experiment. On the other
hand, for the known quadruplex-binding ligand KMR-04-12 (11,
Figure 3), we observed a concentration-dependent enhancement
of the major positive peak at 295 nm, a concentration dependent
appearance of a major negative peak around 260 nm, and a
concentration dependent disappearance of the negative peak
around 240 nm, all confirming association of the ligand with the
telomeric G-quadruplex structure (Figure 6).
Next, a detailed molecular modelling study was carried out to
further confirm the lack of interaction of pyrrolobenzodiazepine
dimers with G-quadruplex DNA. For this study we selected the
PBD dimer PBD2 (10) reported by Raju and co-workers [53], and
the two structurally similar PBD dimers 7 and 8, both of which
have been previously reported in the literature [1,21] and have
similar length and 3-dimensional structure (Figure 4A). Further-
more, an overlay of 7, 8 and 10 shows that each one occupies
similar 3-dimensional space and should cover a near-identical span
of DNA bases (Figure 4B). As the shape and curvature of each
structure is identical, PBD2 (10) would be expected to interact
with duplex rather than quadruplex DNA in a similar manner to 7
and 8. Although we did not have access to PBD2 (10), the shape
similarity between these three PBD dimers should enable
extrapolation of the experimental results obtained to 10. As we
did not observe any notable stabilisation of the G-quadruplex
sequences (including the Tetrahymena G-quadruplex) by either 7
or 8, it would appear unlikely that PBD2 (10) could provide the
strong G-quadruplex stabilisation reported by Raju and co-
workers [53].
Finally, we carried out molecular dynamics studies on the C8-
pyrene conjugate (PBD1, 9, Figure 2) reported by Raju and co-
workers, and the C8-MPB-Py-Py conjugate (5, Figure 1) used in
our study, to elucidate a possible mechanism of binding of these
Figure 5. A & B, CD titration of anthramycin (1) and the C8-PBD-morpholine (3), respectively, with the telomeric G-quadruplex sequence (HT4)
demonstrating a lack of interaction; C & D, CD melting profile of anthramycin:HT4 and C8-PBD-morpholine (3):HT4, respectively. For both molecules
there was no change in CD melting temperature compared to the HT4 DNA alone.
doi:10.1371/journal.pone.0105021.g005
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molecules to quadruplex DNA. In the FRET-DNA melting study,
5 provided modest G-quadruplex stabilisation of up to 2.9uC at a
molar ratio of 50:1 (ligand:DNA). The crystal structure of a
telomeric G-quadruplex (PDB ID: 3CDM) was taken as a starting
point to study plausible interactions with 5 and 9. In both cases,
the MD simulations suggested that quadruplex binding was
mediated exclusively by the C8-linked components and not by the
PBD ring structure itself. In the case of 9, when it was placed over
the G-quartet, the planar pyrene fragment appeared to be ideally
shaped for interaction with the G-quadruplex structure. In the
initial stages of the simulation, the pyrene moiety interacted in a
non-covalent manner with the G-quadruplex sequence, with the
pyrrolobenzodiazepine unit pointing upwards in an orthogonal
position to the pyrene moiety (Figure 7a). As the simulation
progressed, the PBD fragment was gradually pulled further
towards the quadruplex structure, but did not participate in any
significant interactions with the DNA. Further simulations were
undertaken starting with the PBD placed over the G-quadruplex
and the pyrene oriented at an angle orthogonal to the G quartet.
However, in these simulations the PBD shifted away from the
quadruplex structure and was replaced by the pyrene which then
stabilised the G-quadruplex to a much greater extent. In the case
of the PBD-MPB conjugate 5, which exhibited moderate G-
quadruplex stabilisation, simulations of the ligand interacting with
the quadruplex produced similar results to those for the PBD-
Pyrene (9), with the non-covalent moiety (i.e., the C8-MPB-Py-Py
fragment) interacting with the G-quadruplex structure while the
PBD remained outside of the plane of the DNA. These
observations were further supported by free energy of binding
calculations conducted during simulations of the interaction of the
C8-Pyrene conjugate (9) with the G-quadruplex compared to
similar calculations for interaction of the pyrene fragment alone
with the quadruplex. These calculations gave a more favourable
free energy of binding for the pyrene fragment alone (2
19.50 kcal/mol) compared to the C8-Pyrene PBD conjugate (9)
(217.94 kcal/mol), suggesting that the presence of the PBD
fragment may actually reduce DNA interactivity rather than
enhance it. Taken together, these simulations and energy
calculations unequivocally supported our view that it is the non-
covalent C8-moieties of the ligands (i.e., the MPB-Py-Py and
pyrene fragments of 5 and 9, respectively) that direct and facilitate
quadruplex binding rather than the PBD entities themselves,
which have no affinity for quadruplex DNA.
Conclusion
Despite the report by Raju and co-workers [53] that PBD
molecules can stabilise quadruplex DNA structures, we can find no
evidence to substantiate this claim based on FRET thermal
denaturation, CD studies, molecular dynamics simulations and
free energy of binding calculations of the potential interaction of
eight PBD molecules of diverse structure with eight different DNA
quadruplex types. For some PBD-containing molecules we did
observe moderate binding at high molar ratios of ligand/DNA,
but this only occurred to a significant extent for PBD molecules
with large C8-substituents (e.g., 4 and 5). We note that both the
PBD1 (9) and PBD2 (10) molecules studied by Raju and co-
workers had large C8-substituents, and it is likely that they were
Figure 6. CD spectrum of a 5 mM solution of telomeric G-quadruplex with 0–6 equivalents of KMR-04-12 (11), showing dose-
dependent enhancement of the CD signals.
doi:10.1371/journal.pone.0105021.g006
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observing the same non-specific interactions of the C8-substituents
with the quadruplex DNA rather than the PBD moieties
themselves.
We also note that, in their recent report in this journal [53],
Raju and co-workers state that ‘‘PBDs were previously reported to
possess planar structure and intercalate to DNA’’, referring to
work published by Hopkins and co-workers [70] and Kraus and
Selvakumar [71]. In fact, since the discovery of the first PBD
(anthramycin) in the early 1960s [6], there have been no reports of
this family of agents interacting with DNA by intercalation, and it
is widely accepted that they are not planar due to their chiral
C11a(S)-position and interact in the minor groove due to their
inherent isohelicity with the DNA helix.
Figure 7. A, Snapshot of a MD simulation of the PBD-Pyrene conjugate (PBD1, 9) interacting with the telomeric G-quadruplex, showing the the C8-
pyrene component stacking with the G-quartet of the telomeric quadruplex, and the PBD component pointing upwards in an orthogonal orientation
to the pyrene moiety; B, Snapshot of a MD simulation of the C8-PBD conjugate KMR-28-18 (5) interacting with the telomeric G-quadruplex, showing a
similar interaction of the C8-side chain with the quadruplex DNA rather than the PBD moiety itself.
doi:10.1371/journal.pone.0105021.g007
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In summary, we report here experimental evidence that PBD
molecules do not interact to any significant extent with quadruplex
DNA structures. It is important that this is clear in the literature, as
two PBD-based agents are presently in clinical trials and others are
in late-stage pre-clinical development, and so the mechanism of
action of these agents will be under close scrutiny in the future.
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